![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-first-patient-dosed-in-phase-1b2a-clinical-trial-of-tegavivint-in-patients-with-advanced-hepatocellular-carcinoma-who-have-failed-one-or-more-systemic-treatments-302065477.html
https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-the-initiation-of-a-phase-1-clinical-trial-for-tegavivint-in-patients-with-c-myc-overexpressing-relapsed-or-refractory-large-b-cell-lymphomas-301825538.html
https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-results-from-phase-1-dose-escalation-study-of-tegavivint-in-desmoid-tumors-to-be-presented-at-the-2022-asco-annual-meeting-301558729.html
https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-presentation-of-three-posters-involving-research-into-tegavivint-at-the-aacr-2022-annual-meeting-301520693.html
https://www.clinicaltrialsarena.com/news/iterion-phase-i-ii-trial-tegavivint-paediatric-cancers/
https://www.clinicaltrialsarena.com/news/iterion-phase-i-ii-trial-tegavivint-paediatric-cancers/
https://www.prnewswire.com/news-releases/iterion-therapeutics-initiates-enrollment-of-phase-2a-dose-expansion-study-of-tegavivint-in-patients-with-desmoid-tumors-301100338.html